文献-消炎||A型毒素的消炎效果

文献-利尿||A型有毒运用于膝心血管节阻碍治疗十分复杂各城市肿胀症

A型效运用于膝心血管节阻碍治疗十分复杂各城市肿胀症：一项随机试验

Simon背景：Simon

本深入研究目的验证效通过持续升高皮肤气压延长膝心血管阻碍持续时间的假设。编者来进行了一项随机、随机对照、对照试验，深入研究a型效治疗十分复杂各城市肿胀症高血压膝心血管节阻碍的病理。

Simon作法：Simon

采用75 IU A型效（效组）和局部药（对照组），对下肢十分复杂各城市肿胀症高血压来进行膝心血管节阻碍。

主要结果是1个同月后阻碍侧足底与对侧足底的相较温差变化。

次要结果是3个同月后的相较温差变化以及肿胀风速变化。

Simon结果：Simon

共有48名参与者（N=24/组）被随机分配。

效组的相较气压增加高于对照组（分作1.0±1.3℃ vs. 0.1±0.8℃；差异：0.9℃[95%CI：0.3～1.5]；P=0.006）。

维持至术后3个同月，为1.1±0.8 ℃ vs.-0.2±1.2 ℃；P=0.009。

此外，与对照组相较，效组在1个同月（分作（-2.2±1.0 vs.-1.0±1.6；P=0.003）和3个同月（分作（-2.0±1.0 vs.-0.6±1.6；P=0.003）时的肿胀风速明显下降。

没有与效药剂相关的严重不良惨剧。

Simon论点：Simon

在十分复杂各城市肿胀症高血压中，使用A型效来进行膝心血管节阻碍可使患足气压升高3个同月，并可减轻肿胀。

Botulinum Toxin Type A for Lumbar Sympathetic GanglionBlock in Complex Regional Pain Syndrome: A Randomized Trial

Background: The present study was designed totest the hypothesis that botulinum toxin would prolong the duration of a lumbarsympathetic block measured through a sustained increase in skin temperature.The authors performed a randomized, double-blind, controlled trial to investigatethe clinical outcome of botulinum toxin type A for lumbar sympathetic ganglionblock in patients with complex regional pain syndrome.

Methods: Lumbar sympathetic ganglion block wasconducted in patients with lower-extremity complex regional pain syndrome using75 IU of botulinum toxin type A (botulinum toxin group) and local anesthetic(control group). The primary outcome was the change in the relative temperaturedifference on the blocked sole compared with the contralateral sole at 1postoperative month. The secondary outcomes were the 3-month changes inrelative temperature differences, as well as the pain intensity changes.

Results: A total of 48 participants (N = 24/group)were randomly assigned. The change in relative temperature increase was higherin the botulinum toxin group than in the control group (1.0°C ± 1.3 vs. 0.1°C ±0.8, respectively; difference: 0.9°C [95% CI, 0.3 to 1.5]; P = 0.006), whichwas maintained at 3 months (1.1°C ± 0.8 vs. -0.2°C ± 1.2, respectively; P =0.009). Moreover, pain intensity was greatly reduced in the botulinum toxingroup compared with the control group at 1 month (-2.2 ± 1.0 vs. -1.0 ± 1.6,respectively; P = 0.003) and 3 months (-2.0 ± 1.0 vs. -0.6 ± 1.6, respectively;P = 0.003). There were no severe adverse events pertinent to botulinum toxininjection.

Conclusions: In patients with complex regionalpain syndrome, lumbar sympathetic ganglion block using botulinum toxin type Aincreased the temperature of the affected foot for 3 months and also reducedthe pain.